Impower010 nct02486718
WitrynaNCT02486718 (active, not recruiting). Findings Between Oct 7, 2015, and Sept 19, 2024, 1280 patients were enrolled after complete resection. 1269 received ... To our knowledge, the data from IMpower010 are the first to . emerge from the phase 3 studies of adjuvant immunotherapy in stage IB–IIIA NSCLC. Patients with completely resected Witryna• In IMpower010 (NCT02486718), adjuvant atezolizumab demonstrated a statistically significant DFS benefit vs BSC in resected NSCLC following platinum-based chemotherapy at the DFS IA 1 – PD-L1 TC ≥1% stage II-IIIA population analysis: DFS HR, 0.66; 95% CI: 0.50, 0.88
Impower010 nct02486718
Did you know?
Witryna12 kwi 2024 · Dr Felip presented results from the trial at the 2024 European Lung Cancer Congress (ELCC). The IMpower010 trial (ClinicalTrials.gov Identifier: NCT02486718) … Witryna13 wrz 2024 · The primary results of IMpower010 were presented at the 2024 ASCO Annual Meeting (Abstract 8500).Those results included a significant disease-free …
Witryna27 wrz 2024 · Three recent randomized Phase III trials reported significant improvements in disease-free survival with adjuvant immune checkpoint inhibitors or targeted therapy in patients with resectable NSCLC: IMpower010 (atezolizumab vs best supportive care; NCT02486718), KEYNOTE-091 (PEARLS) (pembrolizumab vs placebo; … Witryna23 sty 2024 · Efficacy was demonstrated in a multi-center, randomized, open-label trial (IMpower010, NCT02486718) in patients with stage IB (tumors ≥ 4 cm) through stage …
Witryna10 wrz 2024 · IMpower010 (NCT02486718) enrolled patients with completely resected, stage IB to IIIA NSCLC with an ECOG performance status of 0 or 1, who had undergone lobectomy/pneumonectomy, and had tumor tissue available for PD-L1 analysis. If patients had stage IB tumors, they had to be 4 cm or greater. Witryna30 maj 2024 · A global Phase III, randomized, open-label trial, IMpower010 (NCT02486718), is being conducted to evaluate the efficacy and safety of atezo vs BSC following adjuvant cisplatin (cis)–based chemotherapy (chemo) in pts with resected stage IB (tumors ≥ 4 cm)-IIIA NSCLC.
Witryna29 wrz 2024 · Peters highlight the importance of the phase 3 IMpower010 trial (NCT02486718), which examined the use of adjuvant atezolizumab (Tecentriq) in patients with non–small cell lung cancer, as well as the phase 2 FIRSTMAPP trial, which examined the use of sunitinib (Sutent) in pheochromocytoma and paraganglioma …
Witryna9 paź 2024 · IMpower010 is registered with ClinicalTrials.gov, NCT02486718 (active, not recruiting). Findings: Between Oct 7, 2015, and Sept 19, 2024, 1280 patients were … small chair for bedroom readingWitrynaIMpower010 (NCT02486718) showed a statistically significant benefit in primary-endpoint disease-free survival (DFS) with adjuvant atezo vs BSC in resected stage II … somerview personal care somerset kyWitryna21 cze 2024 · The IMpower010 [NCT02486718] study is the first one to report out at this year’s meeting, and I believe those results will be discussed and potentially integrated into practice. The notion that we could use immune checkpoint inhibitors in early-stage disease to improve overall outcomes is very exciting, and an important step forward in … small chair for bedroom ikeaWitryna20 wrz 2024 · IMpower010 showed a disease-free survival benefit with atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected stage II-IIIA NSCLC, with pronounced benefit in the subgroup whose tumours expressed PD-L1 on 1% or more of tumour cells, and no new safety signals. small chair cushion officeWitrynaIMpower010 (NCT02486718) showed that adjuvant atezo improved disease-free survival (DFS) vs BSC in pts with PD-L1 tumour cell (TC) ≥1% stage II-IIIA NSCLC. While a … small chair covers indoorsWitryna近日,中国国家药品监督管理局（nmpa）已受理君实抗pd-1单抗药物特瑞普利单抗的新适应症上市申请,即联合化疗围手术期治疗并本品单药作为辅助治疗后巩固治疗,用于可切除iii期非小细胞肺癌（nsclc）的治疗。这是特瑞普利单抗在中国递交的第7项上市申请。也有望成为首个治疗可手术肺癌的国产pd1。 small chair cushionsWitryna12 paź 2024 · of patients on adjuvant ATZ were obtained from the IMPower010 (NCT02486718) clinical trial and were applied to quantify the projected decline in the number of eNSCLC patients relapsing over a 10-year period post-ATZ launch relative to best supportive care (BSC) Sensitivity analyses were conducted to assess the … small chair for bathroom